Cleveland HeartLab, LLC (CHL) is a specialty clinical laboratory and disease management company focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. CHL operates a CAP-accredited and CLIA-certified Clinical Laboratory located on the main campus of the Cleveland Clinic and receives samples from doctors’ offices and hospitals all across the country. CHL has developed a profile of tests focused on managing and reducing inflammation, a root cause of heart disease. In addition to their Inflammatory Profile, they have an array of tests that doctors can choose from. One of the company’s proprietary tests, CardioMPO, is an enzyme immunoassay intended for the quantitative determination of myeloperoxidase in human plasma. CHL also runs a research & development laboratory where cardiovascular disease biomarkers are being developed for use in the clinical community. CHL has a significant pipeline of tests that are protected by exclusive intellectual property and target large, under-addressed markets. In addition, an agreement with the Cleveland Clinic provides the company access to intellectual property developed at the Clinic in the areas of cardiovascular and inflammatory biomarkers.